X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28) 28
index medicus (25) 25
animals (23) 23
gray platelet syndrome (17) 17
male (14) 14
female (12) 12
hematology (11) 11
immunology (10) 10
neurosciences (10) 10
platelets (10) 10
multidisciplinary sciences (9) 9
article (8) 8
blood platelets - ultrastructure (8) 8
cell biology (8) 8
medicine (8) 8
science (8) 8
blood platelets (7) 7
medical research (7) 7
mice (7) 7
mutation (7) 7
adult (6) 6
analysis (6) 6
research article (6) 6
blood platelets - metabolism (5) 5
blood proteins - genetics (5) 5
disease (5) 5
gray platelet syndrome - genetics (5) 5
megakaryocytes (5) 5
mice, knockout (5) 5
neurons (5) 5
oncology (5) 5
phenotype (5) 5
proteins (5) 5
aged (4) 4
alpha-granules (4) 4
anatomy (4) 4
biology and life sciences (4) 4
blood (4) 4
blood platelets - pathology (4) 4
brain (4) 4
cells (4) 4
child (4) 4
fibrinogen (4) 4
gene expression (4) 4
genetic aspects (4) 4
inflammation (4) 4
innate immunity (4) 4
medicine & public health (4) 4
medicine and health sciences (4) 4
medicine, experimental (4) 4
middle aged (4) 4
physiology (4) 4
progenitor cells (4) 4
protein (4) 4
rats (4) 4
research and analysis methods (4) 4
rodents (4) 4
stem cells (4) 4
thrombocytopenia - genetics (4) 4
thrombosis (4) 4
activation (3) 3
animal cells (3) 3
blood cells (3) 3
blood proteins - metabolism (3) 3
body fluids (3) 3
bone marrow (3) 3
cell proliferation (3) 3
cellular types (3) 3
central-nervous-system (3) 3
diagnosis (3) 3
diagnosis, differential (3) 3
gene (3) 3
genetics (3) 3
genomics (3) 3
granules (3) 3
gray platelet syndrome - diagnosis (3) 3
health aspects (3) 3
immune system (3) 3
immunophenotyping (3) 3
life sciences (3) 3
medicine, research & experimental (3) 3
multiple sclerosis (3) 3
mutations (3) 3
neuroimmunomodulation - physiology (3) 3
neurology (3) 3
neutrophils (3) 3
neutrophils - metabolism (3) 3
oligodendrocytes (3) 3
pathogenesis (3) 3
pathology (3) 3
patients (3) 3
pedigree (3) 3
platelet (3) 3
platelet aggregation (3) 3
research (3) 3
risk factors (3) 3
signal transduction (3) 3
studies (3) 3
syndrome (3) 3
thrombin (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 03/2016, Volume 11, Issue 3, pp. e0150852 - e0150852
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, p. e0116665
Coagulation factor XII (fXII) is important for arterial thrombosis, but its physiological activation mechanisms are unclear. In this study, we elucidated the... 
C1 INHIBITOR | WHOLE-BLOOD | SUBPOPULATIONS | BLOOD-COAGULATION | ALPHA-GRANULE PROTEIN | THROMBUS FORMATION | MULTIDISCIPLINARY SCIENCES | IN-VIVO | PROCOAGULANT PLATELETS | POLYPHOSPHATES | CONTACT ACTIVATION | Humans | Secretory Vesicles - metabolism | Male | Factor XII - chemistry | Blood Coagulation Factor Inhibitors - pharmacology | Complement C1 Inactivator Proteins - pharmacology | Aged, 80 and over | Adult | Female | Cell Membrane - metabolism | Cell-Derived Microparticles - metabolism | Factor XII - agonists | Gray Platelet Syndrome - metabolism | Complement C1 Inactivator Proteins - metabolism | Enzyme Activation - drug effects | Blood Coagulation - drug effects | Blood Platelets - metabolism | Models, Biological | Factor XII - antagonists & inhibitors | Factor XII - metabolism | Gray Platelet Syndrome - blood | Protein Binding | Family | Aged | Blood Coagulation Factor Inhibitors - metabolism | Phosphates | Thrombin | Hostages | Thrombosis | Blood clot | Pediatrics | Physiological effects | Calcium | Lecithin | Laboratories | Coagulation | Confocal microscopy | Oncology | Activation | Calcium ionophores | Health physics | Inactivation | ADP | Clotting | Proteins | Signal transduction | Immunology | Blood platelets | Physiology | Inhibition | Thromboembolism | Phosphatidylserine | Deactivation | Hematology | Secretion | Pharmacology | Molecular chains | Physics | Blood flow | Coagulation factors | Inhibitors | Microscopy | Collagen | Annexin V | Platelets | Binding sites | Coagulation factor XII
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2017, Volume 127, Issue 9, pp. 3521 - 3526
Journal Article
Journal of Immunology, ISSN 0022-1767, 10/2017, Volume 199, Issue 8, pp. 2948 - 2957
Journal Article
Transfusion Medicine and Hemotherapy, ISSN 1660-3796, 10/2010, Volume 37, Issue 5, pp. 248 - 258
Journal Article
The American Journal of Human Genetics, ISSN 0002-9297, 06/2012, Volume 90, Issue 6, pp. 986 - 1001
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9, p. e74728
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2003, Volume 122, Issue 6, pp. 1031 - 1034
cytarabine | glucocorticoid receptor | sickle cell trait | bone resorption | CFU‐Meg | pseudoemperipolesis | darbepoetin alpha | novel thalassaemia deletion | Vα24+ NKT | alloimmune | 5′‐nucleotidase | mutation screening | DaunoXome | haptoglobin | Hb oxygen saturation | haem oxygenase | hepcidin | FLT3 mutations | vincristine | bone marrow biopsy | hereditary spherocytosis | PML/RARα | immunosuppressive treatment | cytogenetic abnormalities | bFGF | HPC | in vitro assay | drug resistance | amyloidosis | fibrinogen | TAFI polymorphism | transgenic sickle mice | SDF‐1/CXCL12 | front‐face fluorescence | recombinant | thrombin‐generation‐based test | FLIP | myeloma | 2‐chloro‐deoxyadenosine (2‐CdA) | chronic GVHD | Ig/TCR gene | allopurinol | mylotarg | rituximab | HOMOD | molecular genetics | CGH | asymptomatic | combination chemotherapy | lymphomas | neutralizing antibody | lineage commitment | blood | bone marrow | skin rash | viscosity | encephalitis | autologous | Pseudoxanthoma elasticum | treosulfan | all‐trans retinoic acid | tryptase | translocation t(15; 17) | APC resistance | aplastic anaemia | allogeneic bone marrow transplantation | radiation biology | thalidomide | antibodies | dose intensity | hypoxia | defective calcium ionophore‐induced platelet aggregation | Kx protein | P5′ N‐1 gene | myeloid function and development | graft‐versus‐host disease | imatinib | haemopoietic differentiation | aberrant promoter methylation | arsenic | blast crisis | fibroblast colony‐forming unit (CFU‐F) | grey platelet syndrome | TNF‐alpha | vitronectin receptor | transplantation | renal failure | developmental delay | DNA dosage assessment | direct selection | multicentre international sensitivity index (ISI) | child | sickle haemoglobin | erythrocyte metabolism | Rh complex | human platelet antigen | patient self‐management | internal tandem duplication | fibrinolysis | haemoglobinopathy | Down's syndrome | HLA haploidentical 3‐loci mismatched haematopoietic stem cell transplantation | bone marrow transplantation immunology | supervision | beta‐thalassaemia | bisphosphonates | human | peripheral blood stem cells | haemochromatosis | transient myeloproliferative disease | factor VIIa | clinicalclinical outcome | lymphoma | oncogenes | hypochromic anaemia | acute leukaemia | computer modelling | new agents | ATLL | microarrays | isoform gamma | in vitro | iron | platelet | cancer | factor VIII | monoclonal antibodies | chloroma | β2 microglobulin | chemotherapy | encephalopathy | Oscar Ratnoff | sickle cell disease | dendritic cells | overexpression | acute lymphoblastic leukaemia | hairy cell leukaemia | guidelines | haemopoiesis | spatial | plasma cell | amyloid protein AL | stem cells | thrombopoietin | CML | complications (of therapy) | TRAIL | antenatal screening | angiogenesis | classification | deferiprone | haemolytic anaemia | mutation | XK gene | breakpoint characterization | eosinophilic leukaemia | point‐of‐care test (POCT) monitors | chronic graft‐versus‐host disease | myelodysplastic syndromes | blood safety | leukaemia | RhAg | melphalan | dietary anaemia | umbilical cord blood cells | Northern analysis | Waldenström's macroglobulinaemia | cytotoxic T lymphocytes | protein S | cell | imatinib mesylate | ex vivo expansion | bone marrow mesenchymal stem cell | platelet autoantibodies | CYP3A | clinical investigation | myelodysplasia | mutation detection | inflammation | enzyme cytochemistry | in vitro fertilization | protein C | cardiovascular disease | primary splenic marginal zone lymphoma | BMT | varicella‐zoster virus | Akt | thrombosis (venous) | sickle cell | acyclovir | oral | allogeneic transplantation | therapy‐related myelodysplasia | mediator symptoms | ALL | oral contraceptives | 1‐deamino‐8‐d‐arginine vasopressin (DDAVP) | darboepoetin | basic fibroblast growth factor | PTEN | progenitor cells | transfusion | 5‐Aminolaevulinic acid | immunocompromised | non‐Hodgkin's lymphoma | deoxy‐cytidine kinase | iron metabolism | mutations | blood group | NOD/SCID mice | erythropoiesis | osteoblasts | chemosensitivity | chronic | MDS | α‐galactosylceramide | AML | human herpesvirus 6 | multiple myeloma | therapy‐related | diagnosis | PKC | leucocyte‐reduced red blood cells | erythrocyte | long‐term | haematopoietic progenitor cells | magnupodia | chemokine | cohort study | historical sketch | apoptosis | peripheral blood | storage | blood components and products | ankyrin | bcr breakpoints | mass spectrometry | red blood | cisplatin | Epstein–Barr virus | signalling | erythropoietin | haematocrit | blood platelets | O‐glycosylation | follicular lymphoma | tacrolimus | meta‐analysis | transport | interferon | preclinical study | chronic myeloid leukaemia | ETV6–CBFA2 | ALDH | platelet αIIbβ3 fibrinogen receptor | pyrimidine 5′‐nucleotidase deficiency | hereditary | hypogammaglobulinaemia | APL | autoimmune thrombocytopenic purpura | liposomal daunorubicin | interleukin‐1α | cytogenetics | rhabdomyolysis | haemophilia A | stromal‐derived factor 1 | protein | cord blood transplantation | telomere length | prothrombin 20210A mutation | extracorporeal photochemotherapy (ECP) | relapse | murine survivin | chronic haemolytic anaemia | hyperkalaemia | hereditary stomatocytosis | C‐reactive protein | platelets | interferon‐α | denaturing high‐performance liquid chromatography mutation analysis | granules | differentiation therapy | gene expression | isoform | CD20 | platelet membrane glycoproteins | cell fusion | acute promyelocytic leukaemia | real‐time PCR | diversity | GM‐CSF | allogeneic | mantle cell lymphoma | alpha‐thalassaemia | constitutive phosphorylation | phenotype | Fanconi anaemia | red bloodred blood cells | expression | childhood | adhesion | CD1d | McLeod Syndrome | phosphoglycerate kinase deficiency | antisickling agent | prognosis | idiopathic | mastocytosis | enzyme assays | allelic loss | FISH | mortality | minimal residual disease | DHPLC analysis | external quality assessment | myelodysplastic syndrome | pharmacogenetics | long‐term complete remission | clinical validation | cyclosporin A | aberrant | bleeding time | MLL | ABVD | haematopoietic | p16 | MLS | infections | iron deficiency | CD34 | coagulation factors | graft‐versus‐host disease (GVHD) | antithymocyte globulin | deletion 13q | tumour suppressor gene | villous lymphocyte leukaemia | genotype | RNA expression | red cell membrane skeleton | γ‐globin gene | IgG subclasses | Factor VIII inhibitor | oral anticoagulation | acquired Factor VIII deficiency | recombinant haemoglobin mutants | haemoglobin E | proteasome | adults | prothrombin time | CXCR4 | PML‐RARα | T‐cell | Kell antigens | cryohydrocytosis | international normalized ratio | primer extension | autologous transplantation | thrombosis | tin‐metalloporphrins | cytopenia | T‐cell receptor | factor | staging | stem cell plasticity | timed‐sequential therapy | human leukaemia | spectral karyotyping | Glanzmann thrombasthenia | P50 | meridian‐shaped crescents | polymorphisms | natural killer T cells | recombinant human megakaryocyte growth and development factor | G‐CSF | chronic lymphocytic leukaemia | αvβ3 integrin | T‐ALL | risk | trisomy 11q | chemotherapy toxicity | bone marrow cells | FBC | MOPP | AMD‐3100 | acute myeloblastic leukaemia | myelodysplastic | haemoglobin | children | GM‐CSFR | off treatment | cytokines | flow cytometry | myeloperoxydase | splenectomy | prion protein | IgA multiple myeloma | LOH | natural | gene | laboratory haematology | anaemia of chronic disease | chlorosis | lactacystin | resistance | factor V Leiden | allogeneic stem cell transplantation | Fas‐L | iron chelation | childhood ALL | autologous haematopoietic progenitor cell transplantation | MRD | AIHA | chromosomal alterations | iron absorption | infection | 6‐phosphogluconolactonase | haematopoietic precursors | T cells | haematopoietic stem cell transplantation | epitope mapping | clinical use | EBV | ETV6/ABLI | osmotic lysis | T‐cell receptor excision circles (TRECs) | gemtuzumab ozogamicin | glycolipids | caspase‐8 | cell proliferation | cell cycle | specific amplification | aberrant methylation | myeloma cell lines | deep venous thrombosis | osteoclast | incidence | prenatal treatment | myocardial infarction | T‐cell lymphoblastic lymphoma | variant Creutzfeldt–Jacob disease | interleukin‐12 | Henoch–Schönlein purpura | SSCP analysis | T‐cell depletion | natural killer/T‐cell lymphoma | α4β1 integrins | neurotoxicity | innate immunity | haemoglobin stability | post‐transplant lymphoproliferative disorders | thalassaemia intermedia | interleukin 8 | gene arrays | multicycle chemo/radiotherapy | graft‐versus‐leukaemia effect | haemoglobin central cavity | stem cell transplantation | ABCC6 | late‐effects | survival | history | c‐kit | ETV6 | long‐term feto‐maternal microchimaerism | thrombophilia | β‐globin gene | congenital platelet dysfunction | interleukin‐10 | matrix metalloproteinase 9 | therapy‐related leukaemia | HTLV | fludarabine | idiopathic hypereosinophilic syndrome | Network Protein Sequence Analysis (NPSA)web server | falciparum malaria | Latinos | mouse duodenum | circulating tumour cell | thrombin‐activatable fibrinolysis inhibitor (TAFI) | NK cell lymphoma | acute | mobilization | thrombocytopenia | ammonium | genotype–phenotype | risk risk factors | β‐thalassaemia | idiopathic thrombocytopenic purpura | sialylation | stem cell | acute myeloid leukaemia | heart disease | immunotherapy | pathophysiology | solvent/detergent‐treated plasma | glucose‐6‐phosphate dehydrogenase | chelerythrin | cytotoxicity | enzyme | HHV‐6 | anaemia | lymphoplasmacytic lymphoma | VEGF | thrombotic thrombocytopenic purpura | TCR gene rearrangement PCR | fibronectin | assay | Duffy antigen/receptor for chemokines (DARC) | Hodgkin's | CD34+ cells
Journal Article